Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Transformation of strategic partnerships between CROs and sponsors
June 6, 2017
By: Andrew MacGarvey
Managing Director, PHASTAR
There are many reasons why a pharmaceutical company chooses a contract research organization (CRO) for drug development. The selection process is complex and based on several important considerations including: CRO experience, budget, availability of resources, and a trusting relationship between the CRO and sponsor. Outsourcing strategy in the drug development sector is known for its cyclical changes. Companies move between utilizing project-based outsourcing, in-house teams, functional outsourcing, and strategic partnerships in response to the changing global business climate. The requirement to adapt is not unique to trial Sponsors and we should not be surprised that strategic business models need to change as well. Let’s take a step back and look at the real “end game” of clinical research. Over the last few years, trends in the sector have pointed to a strategic model in which CROs are chosen for both their expertise as well as their willingness to invest in the development of a drug. Pharmaceutical companies have realized the strategic advantages of “cost-sharing” and sharing the risks and benefits of drug development, and consequently these types of partnerships are formed based on the goal of reaching an economic target. During the last decade, the academic community has played a larger role in drug discovery and clinical development and has had much to say regarding the “moral obligation” expected from drug development. These types of studies look to “do good,” but often face challenges such as a lack of resources and budget, limits in technology, incomplete understanding of regulatory requirements and trusting partnerships with CROs. How have strategic partnership models in outsourcing changed to encompass this new moral code? We look at traditional versus evolving strategic partnerships and incorporation of social responsibility. Recently, the industry has seen a significant consolidation of the CRO industry despite sponsors increasing the proportion of outsourcing spend going to strategic partnerships. The economic crisis of the last decade combined with the rising costs of drug development (estimated at over $1 billion) have caused a transition to reduced budgets and shrinking product pipelines. Couple the economic aspect with complex regulatory and industry requirements, sponsors are facing truly complex clinical research projects as they struggle to meet financial and legal objectives while pleasing all industry stakeholders. The CROs in turn have their own fiscal objectives and recent deals have seen them write much bigger contracts as they seek to secure meaningful backlog. With volume comes discount, and so margins have come under pressure across the sector. Of equal importance, the CRO has taken on more responsibility in the strategic partnership model ensuring that the sponsors they support are running quality, cost-efficient and ethical trials. There is certainly a place for the strategic partnership but it must evolve to survive the tough climate in which it operates—both economically and in terms of industry and community expectations. Drug development is changing as new technologies come to the fore and the move from the blockbuster business model shifts to a more personalized approach to medicine. Patient groups, academic research units, and charitable organizations are all playing an increasingly important role in drug development. The sector is shifting its focus from massive patient populations and high throughput screening programs to more targeted methodologies that can benefit from these stakeholders. A service provider within a strategic partnership may be required to establish relationships with other players that can help deliver the leaner—and in some cases, more socially responsible—model. For example, by working with a charitable organization, a strong CRO can link the expertise that may reside in this external organization with interested sponsors. There can be a benefit to the CRO in performing pro bono work with patient groups and others to surface viable projects or to provide commercial guidance that can maximize a project’s chance of success. Working in this way also provides the CRO with an opportunity to ‘give back’ in a meaningful way, incorporated into an overall development strategy with the sponsor involved. Vendors who engage in strategic partnerships need to demonstrate ‘value added’ service to counter the erosion of margin that can come with volume and contract length. They must introduce fresh thinking to uncover new areas of benefit to their customers. CROs have tended to take the lead where there has been the need for exposure to risk to deliver a benefit to the industry as a whole. Where this has happened in the past, the change has predominantly come around the introduction of new technology. Now, the new ideas may need to come in terms of process reengineering and in relationship management. Social responsibility in action for Wings for Life Wings for Life is a non-profit organization focused on research for spinal cord injuries. We worked with them on this new strategic partnership model with positive results. We used a model of “accessible expertise” by loaning some of our top management and experts to ongoing clinical trials. The head of Biostatistics Consultancy, Thomas Zwingers, with expertise in study design and protocol analysis, helped Wings for Life perform statistical analyses in order to prepare the study data and reports for potential pharmaceutical partners who were looking to take the study to the next phase of development. To manage the economic aspects of the study, CROS NT’s chairman, Paolo Morelli, supported the company in budget definition and various management aspects. In addition to the obvious benefits for a non-profit like Wings for Life, CROS NT was able to leave a positive impact in the life sciences community and advance treatment for spinal cord research through its corporate social responsibility efforts. CROS NT invested its time and resources to gain experience and demonstrate to pharmaceutical partners that it has the know-how to follow studies through to post-market.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !